PROSCA & BLADDR 2022

 

PROSCA & BLADDR 2022
K

Optimal Strategies for Prostate Cancer Patients Progressing on AR-Pathway Inhibitors: Radioligand Therapy

By PROSCA & BLADDR 2022 FEATURING Ken Herrmann
By PROSCA & BLADDR 2022 FEATURING Ken Herrmann
43 views
December 28, 2022
Comments 0
Login to view comments. Click here to Login
PROSCA
18:23

Multicancer Early Detection

PROSCA & BLADDR 2022

E. Klein

99 views
15:14

The Future of Prostate Cancer Pathology

PROSCA & BLADDR 2022

E. Comperat

124 views
14:25

The Future of External Beam Radiotherapy for Prostate Cancer

PROSCA & BLADDR 2022

A. Bossi

75 views
14:13

A Medical Oncologist’s Perspective on Therapy Development in Prostat…

PROSCA & BLADDR 2022

E. Efstathiou

628 views
13:54

Oligorecurrent Prostate Cancer

PROSCA & BLADDR 2022

J. Murray

159 views
13:58

Optimal Strategies for Prostate Cancer Patients Progressing on AR-Pa…

PROSCA & BLADDR 2022

A. Bahl

115 views
17:24

PARPi in Prostate Cancer: Single Agents and Combinations

PROSCA & BLADDR 2022

E. Castro

137 views
15:09

Optimal Strategies for Prostate Cancer Patients Progressing on AR-Pa…

PROSCA & BLADDR 2022

K. Herrmann

43 views
13:43

Prostate Cancer Treatment Intensification With Chemotherapy: Does Vo…

PROSCA & BLADDR 2022

S. Gillessen

213 views
17:27

Prostate Cancer Treatment Intensification With Radiotherapy: Does Vo…

PROSCA & BLADDR 2022

N. James

137 views
14:51

Prostate Cancer: Managing Cardiovascular and Skeletal Comorbidities

PROSCA & BLADDR 2022

A. Bahl

269 views
17:59

Role of Surgery in Very High-Risk Prostate Cancer

PROSCA & BLADDR 2022

S. Joniau

101 views
17:38

Radiotherapy in Very High-Risk Prostate Cancer

PROSCA & BLADDR 2022

A. Bossi

229 views
14:37

Systemic Treatment in High-Risk Localized Prostate Cancer

PROSCA & BLADDR 2022

K. Fizazi

317 views
14:28

The Added Benefit of New Imaging for (Very) High-Risk Prostate Cance…

PROSCA & BLADDR 2022

A. Padhani

127 views
17:35

Impact of Genomic Classifiers on Postoperative Prostate Cancer Treat…

PROSCA & BLADDR 2022

A. Dal Pra

41 views
08:38

DEBATE: Do We Postpone Salvage RT Until a Positive PSMA-PET/CT? Yes

PROSCA & BLADDR 2022

R. van den Bergh

42 views
08:59

DEBATE: Do We Postpone Salvage RT Until a Positive PSMA-PET/CT? No

PROSCA & BLADDR 2022

J. Murray

56 views
19:11

Follow-Up After Radical Therapy for Prostate Cancer: Not All That Sh…

PROSCA & BLADDR 2022

K. Goffin

119 views
09:37

PSMA-PET/CT-Based RT for Prostate Cancer in Salvage Setting

PROSCA & BLADDR 2022

V. Achard

42 views
09:19

PC-PEP Randomized Trial: The Prostate Cancer - Patient Empowerment P…

PROSCA & BLADDR 2022

G. Ilie

13 views
05:40

MINT Trial: Lymph Node Staging With 18F-PSMA PET/CT in Newly Diagnos…

PROSCA & BLADDR 2022

J. van Basten

31 views
04:41

Adoption of Active Surveillance Protocols for Prostate Cancer Remain…

PROSCA & BLADDR 2022

F. Kapogiannis

12 views
21:32

Genomic Risk Assessment for Active Surveillance in Prostate Cancer

PROSCA & BLADDR 2022

E. Klein

57 views
13:54

Management of Intermediate Risk Prostate Cancer: The Role of Imaging…

PROSCA & BLADDR 2022

A. Padhani

339 views
62:13

Highlights of the Advanced Prostate Cancer Consensus Conference (APC…

PROSCA & BLADDR 2022

A. Omlin, S. Gillessen

30 views
14:47

New Concepts in Prostate Cancer Pathology

PROSCA & BLADDR 2022

E. Comperat

73 views
18:20

Immunotherapy in Prostate Cancer

PROSCA & BLADDR 2022

A. Omlin

37 views
20:52

AR Antagonists for Prostate Cancer: Are They All Equal?

PROSCA & BLADDR 2022

B. Tombal

226 views